Previous Article | Next Article 
Journal of Virology, January 2000, p. 755-763, Vol. 74, No. 2
0022-538X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Glial Cell-Specific Regulation of the JC Virus
Early Promoter by Large T Antigen
Hee-Sun
Kim,
Nuno M.
Goncalves, and
John W.
Henson*
Molecular Neuro-Oncology Laboratory,
Massachusetts General Hospital, Charlestown, Massachusetts 02129, and Harvard Medical School, Boston, Massachusetts 02115
Received 17 June 1999/Accepted 8 October 1999
 |
ABSTRACT |
Progressive multifocal leukoencephalopathy (PML) is a fatal
demyelinating disease that results from an oligodendrocyte infection caused by JC virus. The JC virus early promoter directs cell-specific expression of the viral replication factor large T antigen, and thus
transcriptional regulation constitutes a major mechanism of glial
tropism in PML. We have previously demonstrated that T antigen controls
the JC virus basal promoter in a glial cell-specific manner, since T
antigen repressed the JC virus and simian virus 40 (SV40) early
promoters in glioma cells but induced strong activation of the JC virus
early promoter in nonglial cells. To further analyze these findings, T
antigen and nuclear extracts from glial and nonglial cells were used to
examine DNase I footprints on the proximal promoter. T-antigen binding
to site II was more extensive than expected based on sequence homology
with SV40, and nuclear proteins protected several regions of the
proximal promoter in a cell-specific manner. Multiple Sp1 binding
domains were identified. Site-directed mutagenesis revealed that
T-antigen-mediated activation required a TATA box sequence, a
pentanucleotide repeat immediately upstream of the TATA box, and
an Sp1 binding site downstream of the TATA box. When footprints were
obtained with mutant promoters which blocked T-antigen-induced
transactivation, no change in T-antigen binding was observed. These
results suggest that T antigen activates the JC virus basal promoter in
nonglial cells by interaction with the transcription
initiation complex.
 |
INTRODUCTION |
The human polyomavirus JC virus is
the etiologic agent of progressive multifocal leukoencephalopathy
(PML). JC virus selectively destroys oligodendrocytes, leading to
multiple areas of demyelination and attendant loss of brain function
(3, 31). Once a rare condition, PML is no longer infrequent,
occurring in 5% of individuals with AIDS (4). JC virus
infection exists in a persistent state in kidney tissue and peripheral
blood lymphocytes throughout the life of healthy individuals. In
the setting of immunodeficiency, the virus infects and destroys
oligodendrocytes, producing patches of myelin loss in subcortical white
matter (22). Thus, the neuropathological features suggest
that reactivated JC virus infection is specific for glial cells.
The JC virus early promoter directs cell-specific expression of the
large T antigen, which is required for viral replication, and thus
transcriptional regulation constitutes a major mechanism of glial
tropism of PML (15). The MH1 form of the JC virus promoter was directly isolated from the brain of a PML patient. Its sequence diverges somewhat from that of the original Mad-1 promoter
(11); however, both MH1 and Mad-1 proximal promoters have
sequence identity from the initiating codon for T antigen up to a
pentanucleotide site just upstream of the viral TATA sequence. The
pentanucleotide repeat sequence in MH1 varies by a single base from the
perfect repeats seen in the Mad-1 variant of the promoter. This
sequence conservation implies that this region could be important for
cell specificity.
In a transient transfection analysis, the MH1 JC virus early
promoter activated 30- to 40-fold more transcription in U87MG glioma cells than in HeLa cells (12). Deletion analysis
showed that the tandem repeats of the enhancer region activated gene expression in both glial and nonglial cells, suggesting that the upstream enhancer region is more important for promoter strength than
for cell specificity. Furthermore, the proximal promoter region alone
directed 19-fold more activity in glial cells than in nonglial cells
(13, 19). Thus, the JC virus basal promoter region is able
to direct glial cell-specific gene expression.
The proximal region of the JC virus promoter contains two sequence
homologies with the T-antigen binding sites present in simian virus 40 (SV40) (Fig. 1). In SV40, T antigen
represses its own expression by binding to three sites (LTa I, II, and
III) (25). To evaluate regulation of the JC virus proximal
promoter, we coexpressed JC virus T antigen with the MH1luc reporter in U87MG glioma cells. Increasing levels of T antigen produced the anticipated four- to fivefold repression of the JC virus and SV40 early
promoters. In HeLa cells, by comparison, T antigen produced extremely
strong transcriptional activation of the JC virus promoter, whereas the
SV40 promoter was still repressed fivefold (13). Analysis of
deletion mutants showed that T-antigen activation in nonglial cells
required only the basal promoter region. Thus, T antigen produced glial
cell-specific, divergent regulation of the JC virus basal promoter.

View larger version (15K):
[in this window]
[in a new window]
|
FIG. 1.
(A) Schematic of the MH-1 JC virus and SV40 early
promoters. Open boxes indicate direct tandem repeats of the indicated
number of base pairs, dotted boxes represent TATA homologies, and
striped boxes represent Sp1 binding sites upstream of the TATA
sequence. The SV40 promoter contains three binding sites for the viral
protein large T antigen (black boxes), whereas the JC virus early
promoter contains only sites LTa I and II, based on sequence homology
with SV40 promoter. (B) Comparison of basal promoter region DNA
sequences revealing differences between JC virus and SV40 in the region
between the Sp1 binding sites and the second T-antigen binding site.
|
|
In this study, we analyzed this cell-specific regulation by DNase I
footprinting, using T antigen and glial and nonglial nuclear extracts.
In addition, by site-directed mutagenesis, we identified three
sequences which are critical for T-antigen activation. T-antigen binding was not affected by these mutations. The results suggest that
the initiation complex that forms on the JC virus early promoter participates in cell-specific transcription.
 |
MATERIALS AND METHODS |
Cell culture and transient transfection assays.
U87MG glioma
and HeLa cell lines were grown in Dulbecco's modified Eagle's medium
supplemented with 10% fetal bovine serum (HyClone), streptomycin, and penicillin.
Transfection was performed by a standard calcium phosphate method.
Cells (2 × 10
5 in 60-mm-diameter dishes) were
transfected with 4 µg of the reporter
construct, 1 µg of pSV40-CAT,
various amounts of the effector
plasmid, and pUC19 plasmid to a total
of 10 µg of DNA. pRSV

-gal
and pSV40-CAT produced identical
normalizing activity. Plasmids
used for transient transfection assays
were prepared by using
Qiagen (Santa Clarita, Calif.) columns. After
48 h, cells were
harvested and luciferase assay was performed as
previously described
(
13). To correct for differences in
transfection efficiencies
among different DNA precipitates, luciferase
activity was normalized
to that of chloramphenicol acetyltransferase
determined by a standard
two-phase
assay.
Plasmids.
The pMH1long-luc reporter construct contains the
408-bp upstream sequence of the JC virus large T-antigen gene fused to
the firefly luciferase gene (12). Base substitutions in the
proximal promoter region of the JC virus were generated in the context of the 408-bp upstream sequence, using a QuickChange PCR-based site-directed mutagenesis kit (Stratagene) according to the
manufacturer's procedure. The following oligonucleotides were used in
the mutagenesis procedure with plasmid pMH1long-luc as the template:
5'-GCTCCTCCCTACAGTCCCTTTTTTT-3' and
5'-AAAAAAAAGGGACTGTAGGGAGGAG-3' for the mutant
of the first repeat of pentanucleotides (mPent1),
5'-CCTCCCTACCTTTTCTTTTTTTTA-3' and
5'-ATAAAAAAAAGAAAAGGTAGGGAG-3' for the mutant of
the second repeat of pentanucleotides (mPent2),
5'-TTTTTATATATCCAGGAGGCCGAGG-3' and
5'-GCCTCGGCCTCCTGGATATATAAAA-3' for a TATA
mutant (mTATA2), 5'-CGAGGCCGCCTCTTTTTCCAAGCTTA-3'
and 5'-GTAAGCTTGGAAAAAGAGGCGGCCTC-3' for the Sp1-II mutant, and
5'-CCTCCAAGCTTATGACACGGTAGTAAGGG-3' and
5'-GCCCTTACTACCGTGTCATAAGCTTGGAG-3' for the
novel-sequence mutant. The first set of primers represents
coding-strand sequences of the promoter containing the desired
mutations (underlined bases), and the second set of primers represents
the corresponding noncoding-strand sequences. Constructs with correct
mutations were screened by restriction enzyme digestion and sequencing
analysis. mPent3 contained irrelevant DNA sequence between Sp1-I
site and the polythymidine tract
(5'-CCCTCCTCATGCAGGTTTTTTTT). mTATA1 and
mTATA3 plasmids contained mutated TATA sequences with changes to that
of SV40 (5'-TTTATTTATACAC-3') and irrelevant
sequence (5'-TTTAGCGTCACA-3'), respectively
(13).
pJC-T, which expresses full-length JC virus large T antigen under the
control of the cytomegalovirus promoter, has been described
previously
(
13) and was used as an effector
plasmid.
Preparation of nuclear extracts and DNase I footprinting.
Nuclear extracts were prepared from U87MG human glioma and HeLa cells
as described by Dignam et al. (6). The pellet was resuspended in buffer D (20 mM HEPES [pH 7.9], 20% glycerol, 0.1 M
KCl, 0.2 mM EDTA, 0.2 mM phenylmethylsulfonyl fluoride, 0.5 mM
dithiothreitol [DTT]) and dialyzed against the same buffer. The
extracts were quick-frozen in liquid N2; aliquots were
stored at
70°C and used within 3 months of extraction.
Baculovirus-expressed SV40 T antigen was purchased from Molecular
Biology Resources (Milwaukee, Wis.), and JC virus T antigen was
obtained from Richard J. Frisque (Pennsylvania State University).
Recombinant Sp1 protein was purchased from Promega (Madison, Wis.). The
JC virus early promoter fragment was prepared by PCR and used as a
probe in the DNase I footprinting experiment. For the coding-strand
probe, primer 5'-CAGTTTTTAGCCAGCTCTGCT-3', representing the
coding-strand sequence from bp
146 to
127 of the JC virus promoter
gene, was labeled by [
-32P]ATP, using polynucleotide
kinase. This was used in PCR, together with an unlabeled
oligonucleotide, 5'-GCTTTTTGCAGCAAAAAATTACTGC-3', representing the noncoding nucleotides from bp +84 to +109 of the
JC virus promoter. The noncoding strand probe was prepared by using a
labeled oligonucleotide, 5'-GCTTTTTGCAGCAAAAAATTACTGC-3', representing the noncoding nucleotide sequence from +84 to +109 bp, together with the unlabeled primer
5'-CAGTTTTTAGCCAGCTCTGCT-3', which represents the coding
sequence from bp
146 to
127. The noncoding strand of the SV40 virus
promoter was also synthesized by PCR using a labeled primer,
5'-GGCGTCTTCCATTTTACCAAC-3', representing the noncoding
nucleotide sequences encompassing the start codon of the luciferase
gene from plasmid pA3PLUC together with the unlabeled
primer 5'-AATTAGTCAGCAACCAGGTG-3', which represents the
coding sequence from bp
204 to
185. Using pMH1long-luc or pSV40-luc
plasmid DNA (13) as the template, PCR was performed with
denaturation, annealing, and DNA synthesis steps at 94°C (0.5 min),
55°C (1 min), and 72°C (1 min), respectively, for a total of 30 cycles. The appropriate end-labeled probe was isolated from a 4%
polyacrylamide gel.
The labeled probes of 30,000 cpm were incubated with the above
recombinant proteins or nuclear extracts in 40 µl of binding
buffer
for 25 min at room temperature. After incubation, DNase
I digestion was
performed with freshly diluted DNase I in 1× binding
buffer (20 mM
HEPES [pH 7.9], 2 mM MgCl
2, 50 mM NaCl, 1 mM DTT,
0.1 mM EDTA, 10% glycerol). Two micrograms of poly(dI-dC) was
incubated in the reaction as a nonspecific competitor. The amount
of
DNase I was adjusted empirically for each protein to produce
an even
pattern of partially cleaved products. The DNase I reaction
was stopped
by adding 100 µl of stop buffer (50 mM Tris [pH 8.0],
1% sodium
dodecyl sulfate, 10 mM EDTA [pH 8.0], 0.4 mg of proteinase
K per ml,
100 mM NaCl). Then samples were extracted twice with
phenol-chloroform,
and the DNA was precipitated with 3 volumes
of ethanol. The DNA pellet
was dried and resuspended in sequencing
stop buffer (0.05% xylene
cyanol, 0.05% bromophenol blue, 10 mM
Na
2EDTA, 90%
deionized formamide) and incubated at 95°C for 3
min. Then an aliquot
of sample was loaded onto a 6% polyacrylamide-8
M urea sequencing
gel. The location of each band was determined
by Maxam-Gilbert
sequencing reactions of the labeled
probes.
EMSA.
Sense and antisense oligonucleotides corresponding to
the sequences of Sp1-II 5'-CAGGAGGCCGAGGCCGCCTCCGCCTCCAAGCTTACT-3'
and 5'-GAGTAAGCTTGGAGGCGGAGGCGGCCTCGGCCTCCT-3'
and Sp1-III 5'-CAGAAGTAGTAAGGGCGTGGAGGCTTTTTAG-3' and 5'-CCTAAAAAGCCTCCACGCCCTTACTACTTCT-3' were
synthesized (Gene Link, Inc., Thornwood, N.Y.). These oligonucleotides
were annealed, gel purified, 32P labeled by T4 DNA kinase,
and used as probes. Electrophoretic mobility shift assay (EMSA) and
antibody coincubation experiments were performed with 50,000 cpm of
labeled probe (approximately 0.05 to 0.1 ng) and nuclear extracts (30 µg) in a final volume of 20 µl of 12.5% glycerol, 12.5 mM HEPES
(pH 7.9), 4 mM Tris-HCl (pH 7.9), 60 mM KCl, 1 mM EDTA, and 1 mM DTT
with 1 µg of poly(dI-dC) as described previously (16). For
supershift assay, antibody was coincubated with the nuclear extract mix
for 30 min on ice prior to addition of the radiolabeled probe.
Antibodies against Sp1 and p53 were purchased from Santa Cruz
Biotechnology, Inc. (Santa Cruz, Calif.).
 |
RESULTS |
A T-antigen binding site in the JC virus promoter shows extended
protection.
We have previously shown that T antigen regulates the
JC virus promoter in a manner divergent from the SV40 early promoter, despite highly similar sequences of the T-antigen binding sites in the
two viruses (13). To further study the interaction of T
antigen with the JC virus basal promoter region, DNase I footprinting analysis was performed with the JC virus early promoter (Fig. 2B) and SV40 early promoter (Fig. 2A) as
probes. SV40 T antigen was used because its promoter regulation was
identical to that for JC virus T antigen (13) and it
exhibits a high degree of amino acid homology with JC virus T antigen
(72%) (8). Indeed, using the limited amount of JC virus T
antigen available, we found that the two large T antigens bind in
identical manners to the two promoters (Fig. 2).

View larger version (72K):
[in this window]
[in a new window]
|
FIG. 2.
T-antigen binding to the SV40 and JC virus promoter
regions. The noncoding strands of the SV40 and JC virus were labeled
and used as probes for DNase I footprinting. (A) Footprinting of the
SV40 promoter by large T antigen. Maxam-Gilbert sequencing reaction
mixtures (lanes G/A and C) were used to localize protein binding. The
labeled probe was digested with DNase I in the absence (lane 1) or
presence of 0.1 (lane 2), 0.6 (lane 3), 1.3 (lane 4), or 4.0 (lane 5)
µg of SV40 T antigen (SV40 T) and 1.5 µg of JC virus T antigen
(JCT) (lane 6). T-antigen binding domains (LTa I, LTa II, and LTa III)
are indicated by solid lines. (B) Footprinting of the JC virus promoter
by T antigen. Protein amounts used are the same as for panel A. Two
T-antigen binding domains (LTa I and LTa II) were identified; the
protection of LTa II was much more extensive than expected.
|
|
With increasing concentration of T antigen, footprints became more
prominent with both promoters (Fig.
2). Three binding domains
(LTa I,
LTa II, and LTa III) were identified in the SV40 promoter,
as
previously described (
23). For the JC virus promoter, two
protected areas, encompassing the regions from bp +28 to +64 (LTa
I)
and

27 to +24 (LTa II) relative to the early transcription
start
site, were identified. JC virus LTa II protection was much
more
extensive than expected, based on sequence homology of the
JC virus and
SV40 LTa II sites. Thus, according to sequence homology
with SV40 LTa
II, the expected protection for the JC virus was
from bp

18 to +8.
Interestingly, the JC virus LTa II footprint
extended to cover the TATA
box, which is a major site of sequence
divergence between JC virus and
SV40 basal promoters. T antigen
demonstrated a greater affinity for LTa
I than for LTa II, as
previously shown for the SV40 promoter (Fig.
2)
(
23).
Sequences in the region of extended LTa II protection are critical
for T-antigen-induced transcriptional activation in nonglial
cells.
To further investigate cell-specific regulation by T
antigen, site-directed mutagenesis was performed in the area of
extended T-antigen binding in the LTa II site of MH1 JC virus.
Mutations were made within the pentanucleotide repeats and the TATA
sequence (Fig. 3A). Figure 3B shows the
basal and T-antigen-induced transcription activities for each mutant in
HeLa and U87MG glioma cells. Consistent with previous data, the basal
transcriptional activity of wild-type pMH1long-luc was 30-fold higher
in U87MG cells than in HeLa cells (12). After cotransfection
with a T-antigen expression plasmid, the activity of pMH1long-luc
increased 756-fold in HeLa cells but decreased 3-fold in U87MG
cells. Interestingly, alteration of two specific bases in mPent2
abolished T-antigen-induced transactivation, while the mutation in
mPent1 did not affect either basal or T-antigen-induced transactivation. Alteration of the pentanucleotide sequence to an
irrelevant sequence (mPent3) also abolished the ability of T antigen to
transactivate the promoter.

View larger version (20K):
[in this window]
[in a new window]
|
FIG. 3.
Effects of mutations of the pentanucleotide repeats or
TATA box sequences on basal and T-antigen-induced transcriptional
activity in U87MG and HeLa cell lines. Human glioma U87MG and HeLa
cells were transfected with wild-type (wt) or mutant constructs along
with the empty vector (pRcCMV) or effector plasmid (pJC-T). The molar
ratio of effector plasmid to reporter plasmid used for transfection was
0.1 in each experiment. In each experiment, stimulation of reporter
gene expression by cotransfecting pJC-T is compared to that by
cotransfecting pRcCMV (Invitrogen) and is also presented as fold
induction (average value from three independent samples). (A)
Comparison of nucleotide sequences of the wild-type (wt) and mutated
constructs at the pentanucleotide and TATA box area (brackets). Mutated
bases are indicated; solid lines represent unchanged sequences. (B)
Effects of mutations on the basal and T-antigen-induced transcriptional
activity in U87MG and HeLa cells. The values are averages of triplicate
samples. The cotransfection experiment was repeated at least twice in
each cell line, with nearly identical results.
|
|
In HeLa cells, neither the point mutation altering the JC TATA element
to the SV40 TATA sequence (TAT
TTAT in mTATA1)
nor a
change of the sequence adjacent to the TATA element
(TATATAT
T in mTATA2) affected transcription.
However, change of the TATA
to an irrelevant sequence
(mTATA3) abolished T-antigen-induced
transactivation and decreased
basal activity roughly twofold.
In U87MG cells, the mutations did not
alter T-antigen repression;
however, the irrelevant sequence mTATA3
reduced the basal activity
about fourfold, suggesting that the TATA box
sequence is a functional
element in the basal promoter. These results
suggest an important
role for the second pentanucleotide element and
TATA sequence
for T-antigen-induced transactivation in nonglial
cells.
Cell-specific nuclear proteins interact with the JC virus
basal promoter.
The MH1 JC virus basal promoter is cell specific
in the absence of viral proteins (13, 19). Therefore,
DNase I footprinting analysis of the basal promoter was performed
with nuclear extracts from U87MG and HeLa cells to identify
cell-specific binding proteins (Fig. 4).
Because Sp1 was known to bind to at least one site in the proximal
promoter (11, 12), the footprint of recombinant human Sp1
protein was also obtained.

View larger version (42K):
[in this window]
[in a new window]
|
FIG. 4.
DNase I footprinting analysis of the proximal promoter
region of JC virus. Nuclear extracts from U87MG and HeLa cells and
recombinant human Sp1 were used for DNase I footprinting. The coding
strand probe was labeled as described in Materials and Methods. The
labeled probe was digested with DNase I in the absence (lane 1) or
presence of nuclear extracts prepared from U87MG (lane 2) or HeLa (lane
3) cells or recombinant human Sp1 protein (rhSp1; lane 4). A schematic
diagram corresponding to the digested region of the promoter is also
presented. Areas of protection were identified by both nuclear extracts
in the enhancer region, corresponding to AP1 and NF-1 sites. Areas of
protection were noted in the basal promoter region, most of which
showed a cell-specific pattern. Three Sp1 binding domains were also
identified, as marked by solid lines (Sp1-I, Sp1-II, Sp1-III) at the
right.
|
|
In the enhancer region, AP1 and NF-1 binding sites were seen as
previously reported (Fig.
4) (
1,
28). The Sp1 site
immediately
downstream of the enhancer region is shown to be
footprinted modestly
by both U87MG and HeLa extracts; however, the
patterns of footprinting
for the two extracts differed. Consistent with
previous observations,
recombinant Sp1 protein was shown to protect
this site in the
footprinting analysis (Fig.
4, lane 4; Fig.
5A, Sp1-I). The pentanucleotide
sequence
downstream of the Sp1 site was also protected by both
nuclear extracts.
However, protection by glial extracts was stronger
than that by HeLa
extracts. The TATA sequence was protected preferentially
by U87MG
nuclear extracts compared with HeLa extracts. At bp

6
to +12, another
domain was protected by both extracts. It includes
a sequence,
5'-CCTCCGCCTC-3' (from bp

2 to +8), which contains
a
consensus Sp1 binding site (
7). This domain was also bound
by recombinant Sp1 (Fig.
4, lane 4; Fig.
5A, Sp1-II). An additional
cell-specific domain was detected downstream of Sp1-II at bp +12
to
+29. This domain did not show sequence homology to known transcription
factor binding sites, suggesting that it may represent a novel
regulatory element (Fig.
4) (
7). A third site was also
protected
by recombinant Sp1 (Sp1-III [Fig.
4]) and both nuclear
extracts.
It includes a sequence, 5'-AGGGCGTGG-3' (from bp
+30 to +38) with
80% identity to the consensus Sp1 binding site
(
7).

View larger version (23K):
[in this window]
[in a new window]
|
FIG. 5.
The proximal JC virus promoter contains multiple protein
factor binding sites. (A) Schematic diagram of the upstream regulatory
region of the JC virus promoter. AP1 and NF-1 binding sites were
identified in the enhancer region. The three Sp1 binding sites
identified are marked by open boxes and solid lines. The 5' proximal
region also contains pentanucleotide repeats and TATA box sequences.
Downstream of the Sp1-II site, a novel sequence which was predominantly
protected by U87MG nuclear extract was identified. T-antigen binding
sites are also marked by solid lines. The arrow indicates the
transcription start site. (B) Nucleotide sequence of the MH1 JC virus
promoter from bp 100 to +100 (11). Nuclear protein binding
sites as well as the T-antigen and Sp1 binding sites are represented by
solid lines. The dotted line on the AP1 site indicates a sequence bound
by only U87MG nuclear extracts. The arrow at +1 denotes the
transcription initiation site of the JC virus early gene.
|
|
Nearly identical sequences were protected when either the coding or
noncoding strand was used in footprinting analysis (Fig.
4 and data not
shown). Figure
5 shows a schematic diagram of protein
binding to the JC
virus promoter which summarizes the footprinting
analysis by T antigen,
nuclear extracts, and recombinant Sp1 protein.
The results indicate
that several regions of the basal promoter
DNA were protected in a
cell-specific
manner.
Analysis of Sp1-II, Sp1-III, and the novel protected site.
By
footprinting analysis with recombinant Sp1 protein, two new Sp1 binding
sites were identified (Fig. 4, Sp1-II and Sp1-III). To determine
whether Sp1 proteins from nuclear extracts interact with these sites,
EMSA was performed (Fig. 6). Nuclear
extracts prepared from U87MG and HeLa cells formed cell-specific
complexes with oligonucleotides containing the Sp1-II or Sp1-III
sequences. These complexes contained at least one DNA-protein complex
with similar mobility. In addition, coincubation of U87MG and HeLa nuclear extracts with an Sp1-specific antibody diminished formation of
this complex and produced a new supershifted band (Fig. 6), demonstrating that this complex contains Sp1 protein. In a competition assay, a 100-fold excess of unlabeled Sp1-I or Sp1-II oligonucleotide almost completely abolished the complex formation, but the mutant form
or the irrelevant oligonucleotide did not affect the complex (data not
shown).

View larger version (85K):
[in this window]
[in a new window]
|
FIG. 6.
Sp1-II and Sp1-III are Sp1 binding sites. (A) A 36-bp
oligonucleotide containing the Sp1-II sequence was radiolabeled and
used as a probe; 30 µg of U87MG or HeLa nuclear extract was
coincubated with 0.5 µg of Sp1-specific antibody (lanes 2 and 5) or
with 0.5 µg of p53-specific antibody (lanes 3 and 6). A
sequence-specific complex was formed by both nuclear extracts.
Coincubation with Sp1 antibody but not with p53 antibody diminished
formation of a complex marked by the arrow and resulted in formation of
a supershifted band (indicated by the arrowhead at the top). Unbound
free probe (F) is indicated by the lower arrowhead. (B) A 31-bp
oligonucleotide containing the Sp1-III sequence was radiolabeled, and
an antibody supershift assay was performed as for panel A. The arrow
indicates the DNA-Sp1 complex, and the arrowhead at the top indicates a
supershifted band.
|
|
By footprinting analysis with nuclear extracts, three new binding
domains were identified downstream of the TATA box (Fig.
4 and
5). To
determine whether the Sp1-II and novel sequences
were involved in
T-antigen-induced transactivation, site-directed
mutagenesis was
performed (Fig.
7). Mutation of the
Sp1-II sequence
abolished T-antigen-mediated activation, whereas
mutation of the
novel sequence reduced induction about fivefold.
T-antigen repression
in U87MG cells was unchanged for both mutants. In
contrast, mutation
of the Sp1 site upstream of the pentanucleotide
sequence (Sp1-I)
did not affect T-antigen-induced transactivation
(
13).

View larger version (15K):
[in this window]
[in a new window]
|
FIG. 7.
Effects of mutations of Sp1-II and the novel protected
site on basal and T-antigen-induced transcriptional activity in U87MG
and HeLa cells. Cotransfection was performed as described for Fig. 3.
(A) Comparison of nucleotide sequences of the wild-type (wt) and
mutated constructs of Sp1-II and novel sites. (B) Effects of mutations
on the basal and T-antigen-induced transcriptional activity in U87MG
and HeLa cells.
|
|
Mutation of DNA motifs important for T-antigen-induced
transactivation do not affect T-antigen binding.
To address
whether any of the above mutations affected T-antigen
binding, footprinting analysis was performed with mutants of the pentanucleotide sequence (mPent3), TATA
element (mTATA3), Sp1-II, and novel sequence. T antigen was
incubated with these mutant probes in addition to a wild-type probe,
and footprints were compared (Fig. 8). In
the absence of T antigen, the DNA digestion patterns of each mutant
were slightly modified at the site of mutation. The binding of T
antigen to LTa I and LTa II was not significantly changed by the
mutation in the pentanucleotide sequence, which had abolished
activation (Fig. 8, lane 7). In the case of the irrelevant TATA mutant,
protection by T antigen was stronger than that of the wild-type
sequence (lane 8). The Sp1-II mutant reduced T-antigen binding
moderately (lane 9). These results suggests that T antigen regulates
the JC virus promoter largely by protein-protein interactions
surrounding the TATA site rather than by direct DNA binding.

View larger version (56K):
[in this window]
[in a new window]
|
FIG. 8.
Effects of mutations on T-antigen binding to the JC
virus promoter. The noncoding-strand probes were prepared with
wild-type (WT; lanes 1 and 6), pentanucleotide mutant (lanes 2 and 7),
TATA mutant (lanes 3 and 8), Sp1 mutant (lanes 4 and 9), and
novel-sequence mutant constructs (lane 5 and 10). Each probe was
digested with DNase I in the absence (lanes 1 to 5) or presence (lanes
6 to 10) of T antigen (T-Ag). The T-antigen binding sites are marked by
solid lines at the right. Only the Sp1 mutant altered T-antigen binding
to the promoter.
|
|
 |
DISCUSSION |
This study characterizes the basal region of the glial
cell-specific JC virus early promoter. Two T-antigen binding sites were
identified as protected regions in DNase I footprinting analysis using
recombinant large T antigen. The LTa II protection was much more
extensive than anticipated, based on sequence homology with the SV40
promoter. Nuclear extracts from glial and HeLa cells protected multiple
regions of the JC virus basal promoter in a cell-specific manner, and
these regions overlap the sites of T-antigen binding. By site-directed
mutagenesis, sequences which are critical for T-antigen activation were
also identified. These mutants failed to block the binding of T
antigen, suggesting that protein-protein interactions, rather than
direct DNA binding, are responsible for T-antigen activation.
We previously demonstrated that T antigen repressed JC virus and SV40
early promoters four- to fivefold in U87MG glioma cells (13). In contrast, T antigen induced strong activation of
the JC virus early promoter in nonglial cells, whereas the SV40
promoter was repressed. T antigen also activates the JC virus early
promoter in other nonglial cells (e.g., Saos and U20S osteosarcoma
cells and JEG3 choriocarcinoma cells [data not shown]). The
activation of the JC virus early promoter could represent either
transactivation or derepression. T antigen activates a larger number of
cellular and viral promoters in vitro and in vivo (24, 30).
Simple basal promoter regions are sufficient for transactivation, and a
wide variety of transcription factor binding sites can cooperate with T antigen in activation (5, 10). T antigen lacks a
strong activation domain, and DNA binding is not required. T
antigen can interact with TATA binding protein (TBP), can discriminate between TATA sequences for transactivation, and can substitute for
TBP-associated factor TAFII250 (5), strongly
suggesting a role in transcription initiation. Thus, the divergent
regulation of the JC virus early promoter could reflect cell-specific
or TATA-specific TFIID complexes. Indeed, the ability of TATA and pentanucleotide mutations to abolish T-antigen induction suggests that
regions surrounding the TATA box are crucial for this effect. Also, the
differences in footprinting over the TATA region between the glial and
HeLa nuclear extracts support this hypothesis.
The results could also be explained by a derepression mechanism, as
observed in the cellular hsp70 promoter (17). The
adenovirus protein E1A activates the hsp70 promoter in a
TATA sequence-specific manner by dissociating a 19-kDa repressor, Dr1,
from TBP. Similarly, a repressor could bind the JC virus basal promoter
and inhibit T-antigen expression in nonglial cells. In this model,
transcriptional activity would increase through derepression by T
antigen. Cell-specific methylation in the GC-rich basal promoter
region, as discussed below, constitutes another potential mechanism for
T-antigen regulation (27). Our results do not permit a clear
distinction between activation and derepression, although the fact that
none of the mutations produced a significant change in the basal
expression in HeLa cells might argue for the former.
By footprinting analysis, two T-antigen binding sites were identified
on the JC virus early promoter (Fig. 2). LTa I sites were protected
similarly in JC virus and SV40 promoters, as expected from sequence
homologies. However, JC virus LTa II protection was much larger than
expected. Intriguingly, the more extensive JC virus LTa II footprint
covers the basal promoter region that has been implicated in glial
cell-specific expression, and the upstream portion of the footprint
covers the TATA sequences.
Several investigators have demonstrated the lack of a glial
cell-specific DNase I footprint on the enhancer region of the Mad-1 JC
virus early promoter (1, 2, 29). In the enhancer region,
NF-1 and AP1 binding sites were identified, but no differences in
binding pattern from glial and HeLa extracts were found, except that
the 5' marginal protection of the AP1 site by U87MG nuclear extracts is
more extensive than in HeLa extract (Fig. 4). Although the binding
patterns of the two extracts for the NF-1 site appear similar,
alternative forms of NF-1 might bind to this site as reported
previously (18, 28).
By comparison, there is cell-specific protein binding to the proximal
JC virus promoter (Fig. 4). Immediately downstream of the enhancer
region, a site which was weakly protected by both nuclear extracts but
in slightly different manners was identified. Recombinant human Sp1
protein strongly protected this site, consistent with our previous data
which demonstrated that this is functional Sp1 binding site (11,
12). Downstream of this site, two additional areas of protection
were identified by recombinant Sp1 protein. Within these areas, two Sp1
binding sites were identified by consensus sequence (7), and
antibody supershift analysis indicated that all three sites are Sp1
binding sites (Fig. 6). All three Sp1 motifs are near the TATA box. Sp1
is known to be a ubiquitous transcription factor that controls numerous
cellular and viral genes, including housekeeping, signal
pathway-induced, and tissue-specific genes (14). Based on
its frequent occurrence in CpG islands, one possible mechanism
underlying transcriptional control by Sp1 may be its role in
maintaining methylation-free CpG islands in active genes (9,
21). In vitro methylation of the MH1 JC virus early promoter
leads to very strong repression of transcription after transfection
into glial cells (data not shown). Thus, cell-specific methylation is
another potential mechanism regulating JC virus early gene expression.
The pentanucleotide repeats (5'-TACCTTCCCT) immediately
upstream of the TATA sequence were protected by both U87MG and HeLa nuclear extracts, with the U87MG footprint giving stronger protection. Because this region differs in sequence from the SV40 basal promoter, it was considered to be a potential binding site for a transcriptional repressor. Although several proteins that bind to this sequence have
been identified, their relevance to glial cell specificity remains
unclear (20, 26). In the present study, mutation of this
pentanucleotide sequence did not affect basal transcriptional activity
in either HeLa or U87MG cells. However, it clearly plays an important
role in T-antigen-induced activation.
The TATA box was more strongly protected by U87MG nuclear extracts than
by HeLa extracts, and the pattern of protection was slightly different
as well. This finding was consistent with the data from the mutational
analysis (Fig. 3), in which the irrelevant TATA mutant reduced baseline
expression more strongly in U87MG cells than in HeLa cells. Thus, the
JC virus promoter is TATA dependent in each cell type, but with
significant differences. Moreover, mutation of TATA sequence abolished
T-antigen activation. Thus, the TATA box appears to be a crucial
element not only for basal transcription but also for
T-antigen-mediated transcription of the JC virus promoter.
A strong footprint was found downstream of the second Sp1 site,
straddling the junction between LTa I and LTa II, with U87MG nuclear
extracts. This sequence does not show homology to any known
transcription factor binding site (7). To investigate the
functional importance of this novel sequence, site-directed mutagenesis
was performed. The mutation produced a fivefold reduction in T-antigen
activation but did not cause any change in basal promoter activity.
In summary, site-directed mutagenesis reveals several DNA motifs which
are critical for T-antigen activation. In particular, the DNA sequences
surrounding the TATA box were found to be very important.
Interestingly, alteration of two specific bases residing within the
second pentanucleotide repeat abolished T-antigen-induced activation.
The change of TATA or the second Sp1 into an irrelevant sequence also
abolished activation. The binding of T antigen was not significantly
altered by mutations (Fig. 8). These results suggest that the
transcription initiation complex that forms on the JC virus early
promoter controls cell-specific transcription. The mutations may change
the binding of the cognate protein factors rather than the binding of T
antigen itself. These findings are in sharp contrast to the steric
hindrance model for T-antigen repression of the SV40 or JC virus
promoter (23).
 |
ACKNOWLEDGMENTS |
This work was supported by NIH grant NS35735 to J.W.H.
We thank Richard Frisque for his generous gift of the JC virus T antigen.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Molecular
Neuro-Oncology Laboratory, Massachusetts General Hospital, 149 13th
St., Charlestown, MA 02129. Phone: (617) 726-5510. Fax: (617)
726-5079. E-mail: henson{at}helix.mgh.harvard.edu.
 |
REFERENCES |
| 1.
|
Amemiya, K.,
R. Traub,
L. Durham, and E. O. Major.
1992.
Adjacent nuclear factor-1 and activator protein binding sites in the enhancer of the neurotropic JC virus.
J. Biol. Chem.
267:14204-14211[Abstract/Free Full Text].
|
| 2.
|
Amemiya, K.,
R. Traub,
L. Durham, and E. O. Major.
1989.
Interaction of a nuclear factor-1-like protein with the regulatory region of the human polyomavirus JC virus.
J. Biol. Chem.
264:7025-7032[Abstract/Free Full Text].
|
| 3.
|
Astrom, K.-E.,
E. L. Mancall, and E. P. Richardson.
1958.
Progressive multifocal leukoencephalopathy.
Brain
81:93-111[Free Full Text].
|
| 4.
|
Bacellar, H.,
A. Munoz,
E. N. Miller,
B. A. Cohen,
D. Besley,
O. A. Selnes,
J. T. Becker, and J. C. McArthur.
1994.
Temporal trends in the incidence of HIV-1-related neurological diseases.
Neurology
44:1892-1900[Abstract/Free Full Text].
|
| 5.
|
Damania, B., and J. C. Alwine.
1996.
TAF-like function of SV40 large T antigen.
Genes Dev.
10:1369-1381[Abstract/Free Full Text].
|
| 6.
|
Dignam, J. D.,
R. M. Lebovitz, and R. G. Roeder.
1983.
Accurate transcription initiation by RNA polymerase II in a soluble extract from mammalian nuclei.
Nucleic Acids Res.
11:1475-1489[Abstract/Free Full Text].
|
| 7.
|
Faisst, S., and S. Meyer.
1992.
Compilation of vertebrate-encoded transcription factors.
Nucleic Acids Res.
20:3-26[Free Full Text].
|
| 8.
|
Frisque, R. J.,
G. L. Bream, and M. T. Canella.
1984.
Human polyomavirus JC virus genome.
J. Virol.
51:458-469[Abstract/Free Full Text].
|
| 9.
|
Graff, J. R.,
J. G. Herman,
S. Myohanen,
S. B. Baylin, and P. M. Vertino.
1997.
Mapping patterns of CpG island methylation in normal and neoplastic cell implicates both upstream and downstream regions in de novo methylation.
J. Biol. Chem.
272:22322-22329[Abstract/Free Full Text].
|
| 10.
|
Gruda, M., and J. C. Alwine.
1991.
Simian virus 40 (SV40) T-antigen transcriptional activation mediated through the Oct/SPH region of the SV40 late promoter.
J. Virol.
65:3553-3558[Abstract/Free Full Text].
|
| 11.
|
Henson, J.,
J. Saffer, and H. Furneaux.
1992.
The transcriptional factor Sp1 binds to the JC virus promoter and is selectively expressed in glial cells in human brain.
Ann. Neurol.
32:72-77[CrossRef][Medline].
|
| 12.
|
Henson, J. W.
1994.
Regulation of the glial-specific JC virus early promoter by the transcription factor Sp1.
J. Biol. Chem.
269:1046-1050[Abstract/Free Full Text].
|
| 13.
|
Henson, J. W.,
B. L. Schnitker,
T.-S. Lee, and J. McAllister.
1995.
Cell-specific activation of the glial-specific JC virus early promoter by large T antigen.
J. Biol. Chem.
270:13240-13245[Abstract/Free Full Text].
|
| 14.
|
Kadonaga, J. T.,
K. R. Carner,
F.R. Masiarz, and R. Tjian.
1987.
Isolation of cDNA encoding transcription factor Sp1 and functional analysis of the DNA binding domain.
Cell
51:1079-1090[CrossRef][Medline].
|
| 15.
|
Kenny, S.,
V. Natarajan,
D. Strike,
G. Jhoury, and N. P. Salzman.
1984.
JC virus enhancer-promoter active in human brain cells.
Science
226:1337-1339[Abstract/Free Full Text].
|
| 16.
|
Kim, H. S.,
H. Seo,
C. Yang,
J.-F. Brunet, and K. S. Kim.
1998.
Noradrenergic-specific transcription of the dopamine -hydroxylase gene requires synergy of multiple cis-acting elements including at least two Phox2a-binding sites.
J. Neurosci.
18:8247-8260[Abstract/Free Full Text].
|
| 17.
|
Kraus, V. B.,
J. A. Inostroza,
K. Yeung,
D. Reinberg, and J. R. Nevins.
1994.
Interaction of the Dr1 inhibitory factor with the TATA binding protein is disrupted by adenovirus E1A.
Proc. Natl. Acad. Sci. USA
91:6279-6282[Abstract/Free Full Text].
|
| 18.
|
Krebs, C. J.,
B. Dey, and K. Kumar.
1996.
The cerebellum-enriched form of nuclear factor I is functionally different from ubiquitous nuclear factor I in glial-specific promoter regulation.
J. Neurochem.
66:1354-1361[Medline].
|
| 19.
|
Krebs, C. J.,
M. T. McAvoy, and G. Kumar.
1995.
The JC virus minimal core promoter is glial cell specific in vivo.
J. Virol.
69:2434-2442[Abstract].
|
| 20.
|
Liu, M.,
K. U. Kumar,
M. M. Pater, and A. Pater.
1998.
Identification and characterization of a JC virus pentanucleotide repeat element binding protein: cellular nucleic acid binding protein.
Virus Res.
58:73-82[CrossRef][Medline].
|
| 21.
|
Macleod, D.,
J. Charlton,
J. Mullins, and A. P. Bird.
1994.
Sp1 sites in the mouse aprt gene promoter are required to prevent methylation of the CpG island.
Genes Dev.
8:2282-2292[Abstract/Free Full Text].
|
| 22.
|
Major, E. O.,
K. Amemiya,
C. S. Tornatore,
S. A. Houff, and J. R. Berger.
1992.
Pathogenesis and molecular biology of progressive multifocal leukoencephalopathy, the JC virus-induced demyelinating disease of the human brain.
Clin. Microbiol. Rev.
5:49-73[Abstract/Free Full Text].
|
| 23.
|
Myers, R. M.,
D. C. Rio,
A. K. Robbins, and R. Tjian.
1981.
SV40 gene expression is modulated by the cooperative binding of T antigen to DNA.
Cell
25:373-384[CrossRef][Medline].
|
| 24.
|
Rice, P. W., and C. N. Cole.
1993.
Efficient transcriptional activation of many simple modular promoters by simian virus 40 large T antigen.
J. Virol.
76:6689-6697[Abstract/Free Full Text].
|
| 25.
|
Rio, D. C., and R. Tjian.
1983.
SV40 T antigen binding site mutations that affect autoregulation.
Cell
32:1227-1240[CrossRef][Medline].
|
| 26.
|
Sharma, A. K., and G. Kumar.
1991.
A 53 kDa protein binds to the negative regulatory region of the JC virus early promoter.
FEBS Lett.
281:272-274[CrossRef][Medline].
|
| 27.
|
Slack, A.,
N. Cervoni,
M. Pinard, and M. Szyf.
1999.
DNA methyltransferase is a downstream effector of cellular transformation triggered by simian virus 40 large T antigen.
J. Biol. Chem.
274:10105-10112[Abstract/Free Full Text].
|
| 28.
|
Sumner, C.,
T. Shinohara,
L. Durham,
R. Traub,
E. O. Major, and K. Amemiya.
1996.
Expression of multiple classes of the nuclear factor-1 family in the developing brain: differential expression of two classes of NF-1 genes.
J. Neurovirol.
2:87-100[Medline].
|
| 29.
|
Tada, H.,
M. Lashgari,
J. Rappaport, and K. Khalili.
1989.
Cell type-specific expression of JC virus early promoter is determined by positive and negative regulation.
J. Virol.
63:463-466[Abstract/Free Full Text].
|
| 30.
|
Taylor, I. A. C.,
W. Solomon,
B. M. Weiner,
P. Paucha,
M. Bradley, and R. E. Kingston.
1989.
Stimulation of the human heat shock 70 promoter in vitro by simian virus 40 large T antigen.
J. Biol. Chem.
264:16160-16164[Abstract/Free Full Text].
|
| 31.
|
Zu Rhein, G. M., and S.-M. Chou.
1965.
Particles resembling papova viruses in human cerebral demyelinating disease.
Science
148:1477-1479[Abstract/Free Full Text].
|
Journal of Virology, January 2000, p. 755-763, Vol. 74, No. 2
0022-538X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Kim, S.-Y., Woo, M.-S., Kim, W.-K., Choi, E.-C., Henson, J. W., Kim, H.-S.
(2003). Glial Cell-Specific Regulation of the JC Virus Early Promoter by Histone Deacetylase Inhibitors. J. Virol.
77: 3394-3401
[Abstract]
[Full Text]